MannKind Co. (NASDAQ:MNKD) EVP David Thomson Sells 23,537 Shares

MannKind Co. (NASDAQ:MNKD) EVP David Thomson sold 23,537 shares of the business’s stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $4.66, for a total value of $109,682.42. Following the transaction, the executive vice president now owns 873,616 shares of the company’s stock, valued at approximately $4,071,050.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

MannKind Stock Performance

Shares of MannKind stock opened at $4.82 on Thursday. The company has a market capitalization of $1.31 billion, a PE ratio of 160.72 and a beta of 1.34. The company has a 50-day simple moving average of $4.43 and a two-hundred day simple moving average of $3.96. MannKind Co. has a one year low of $3.17 and a one year high of $5.75.

MannKind (NASDAQ:MNKD) last announced its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.02. The company had revenue of $66.26 million during the quarter, compared to the consensus estimate of $60.55 million. MannKind had a net margin of 3.78% and a negative return on equity of 3.35%. MannKind’s revenue was up 63.1% compared to the same quarter last year. During the same period last year, the firm earned ($0.04) earnings per share. On average, equities analysts predict that MannKind Co. will post 0.1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MannKind

A number of large investors have recently modified their holdings of MNKD. Price T Rowe Associates Inc. MD raised its position in MannKind by 5.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 172,054 shares of the biopharmaceutical company’s stock valued at $780,000 after acquiring an additional 9,410 shares in the last quarter. EntryPoint Capital LLC grew its holdings in MannKind by 60.9% in the 1st quarter. EntryPoint Capital LLC now owns 23,809 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 9,008 shares in the last quarter. ProShare Advisors LLC raised its holdings in shares of MannKind by 9.0% during the 1st quarter. ProShare Advisors LLC now owns 65,811 shares of the biopharmaceutical company’s stock worth $298,000 after acquiring an additional 5,416 shares during the period. Susquehanna Fundamental Investments LLC acquired a new position in shares of MannKind during the 1st quarter valued at about $450,000. Finally, 9258 Wealth Management LLC purchased a new stake in shares of MannKind in the first quarter valued at about $51,000. Hedge funds and other institutional investors own 49.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Wedbush reissued an “outperform” rating and set a $10.00 price target on shares of MannKind in a research report on Wednesday, February 28th. Cantor Fitzgerald reissued an “overweight” rating and set a $6.50 target price on shares of MannKind in a research report on Thursday, May 9th.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.